Daiwa Securities Group
ACRS icon

Daiwa Securities Group’s Aclaris Therapeutics ACRS Stock Holding History

Daiwa Securities Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-248
Closed – – 1279
2024
Q3 		$0 Hold
248
– – ﹤0.01% 1270
2024
Q2 		$0 Hold
248
– – ﹤0.01% 1313
2024
Q1 		$0 Hold
248
– – ﹤0.01% 1313
2023
Q4 		$0 Hold
248
– – ﹤0.01% 1320
2023
Q3 		$2K Hold
248
– – ﹤0.01% 1208
2023
Q2 		$3K Hold
248
– – ﹤0.01% 1210
2023
Q1 		$2K Hold
248
– – ﹤0.01% 1201
2022
Q4 		$4K Hold
248
– – ﹤0.01% 1162
2022
Q3 		$4K Hold
248
– – ﹤0.01% 1168
2022
Q2 		$3K Buy
248
+69
+39% +$967 ﹤0.01% 1194
2022
Q1 		$3K Hold
179
– – ﹤0.01% 1207
2021
Q4 		$3K Buy
+179
New +$2.71K ﹤0.01% 1233
2019
Q4 		– Sell
-170
Closed – – 1199
2019
Q3 		$0 Hold
170
– – ﹤0.01% 1177
2019
Q2 		$0 Hold
170
– – ﹤0.01% 1201
2019
Q1 		$1K Hold
170
– – ﹤0.01% 1156
2018
Q4 		$1K Hold
170
– – ﹤0.01% 1123
2018
Q3 		$2K Hold
170
– – ﹤0.01% 1120
2018
Q2 		$3K Hold
170
– – ﹤0.01% 1117
2018
Q1 		$3K Buy
+170
New +$3.6K ﹤0.01% 1099

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Daiwa Securities Group's ACRS Position: Q4 2024 in Review

Daiwa Securities Group sold out of Aclaris Therapeutics (ACRS) in Q4 2024, closing a stake of 248 shares.

Daiwa Securities Group first reported a position in ACRS in Q1 2018 and held it in 19 quarters. The position peaked at $4K in Q4 2022. 98 funds tracked by Wall St. Rank hold ACRS as of Q4 2024.

  • Daiwa Securities Group reported no remaining Aclaris Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Daiwa Securities Group sold 248 Aclaris Therapeutics shares in Q4 2024.
  • Daiwa Securities Group first reported a position in Aclaris Therapeutics in Q1 2018 and held it in 19 quarters.
  • Daiwa Securities Group's Aclaris Therapeutics position peaked at $4K in Q4 2022.
  • 98 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2024.

Based on Daiwa Securities Group's 13F filing for Q4 2024, filed 7 Feb 2025.